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Abstract
Backround Retinal cavernous hemangiomas are rare vascular
anomalies, and can be associated with cerebral cavernous
malformations (CCM). Distinct mutations have been reported
in patients who have both CCMs and retinal cavernous
hemangiomas.
Methods Fluorescein angiography, spectral domain optical
coherence tomography, and genetic testing were performed
on a patient with a retinal cavernous hemangioma and a
CCM.
Results Our patient was heterozygous in the KRIT1/CCM1
gene for a frameshift mutation, c.1088delC. This would be
predicted to result in premature protein termination.
Discussion We have identified a novel mutation in the
KRIT1/CCM1 gene in a patient with both CCM and retinal
cavernous hemangioma. We hypothesize that the occurrence
of retinal cavernous hemangiomas and CCMs is underlaid by
a common mechanism present in the KRIT1/CCM1 gene.
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Introduction
Cerebral cavernous malformations (CCMs) are congenital
vascular anomalies of the brain that can cause significant
neurological disabilities. Similar vascular anomalies can
also occur in the retina, and are referred to as retinal
cavernous hemangiomas. Retinal cavernous hemangiomas
are rare, and are associated with CCMs in approximately
5% of familial cases [1]. Distinct mutations have been
reported in patients who have both CCMs and retinal
cavernous hemangiomas [1–3]. We report what is, to our
knowledge, a novel frameshift mutation in KRIT1(Krev
interaction trapped-1)/CCM1) gene which was associated
with a retinal cavernous hemangioma and a CCM.
Methods and results
An asymptomatic 30-year-old woman was referred for
evaluation of a retinal mass in her right eye. Visual acuity
was 20/20 in her right eye and 20/15 in her left eye.
External, pupil, motility and anterior segment examinations
were unremarkable. Fundus examination of the right eye
revealed an elevated, dark red macular lesion with multiple
saccular aneurysms (Fig. 1a). Fluorescein angiography
showed a mass with hyperfluorescent areas and inferior
blockage hypofluorescence consistent with a retinal
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the left eye was unremarkable. A CCM was present on
cerebral imaging. Family history, based on self-reporting
and medical records, revealed CCMs in seven of her
family members, which included most of her mother’
brothers and sister. Her mother and grandmother also had
a retinal cavernous hemangioma in association with a
CCM (Fig. 2). Genetic evaluation of our patient, using
genomic DNA extracted from our patient’sb l o o dc e l l s ,
involved sequencing of the full coding regions of all
coding exons (1–16) of the KRIT1/CCM1gene as well as
approximately 50 flanking bases. The patient was hetero-
zygous in the KRIT1/CCM1 gene for a frameshift
mutation, c.1088delC. This would be predicted to result
in premature protein termination. The other family
members were not accessible for clinical evaluation and
DNA sampling for confirmation.
Discussion
CCM can occur in either a sporadic or familial form.
Familial CCMs show autosomal dominant inheritance, and
may be associated with retinal cavernous hemangiomas [4].
A large deletion of the MGC4607 gene, a de novo deletion
of the PDCD10 gene and three different mutations in the
KRIT1/CCM1 gene have been identified in patients with
both CCM and retinal cavernous hemangioma [1–3]. We
have identified a novel mutation in the KRIT1/CCM1 gene
in this patient with both CCM and retinal cavernous
hemangioma.
The KRIT1/CCM1 gene encodes a protein that affects
endothelial cell structure and function, and strong
labeling of KRIT1 expression has been detected in both
the brain and retina [5, 6]. Given our results in
conjunction with three previously reported and different
mutations in the KRIT1/CCM1 region, it is reasonable to
hypothesize that the occurrence of retinal cavernous
hemangiomas and CCMs are underlaid by a common
mechanism present in this gene. All patients with a retinal
cavernous hemangioma should undergo some type of
cerebral imaging, (e.g. MRI or CT scan) to determine the
presence of a CCM. If a patient is found to have both
lesions, it is reasonable to perform a genetic evaluation
from patient’s blood cells to sequence the KRIT1/CCM1
gene. However, genetic diagnostics alone in a patient who
presents with a retinal cavernous hemangioma is not a
substitute for the neurologic and systemic workup that is
required, since the condition is genetically heterogeneous.
Though genetic results to date have no implication with
regard to health or prognosis, the demonstration of a
causative mutation in the KRIT1/CCM1 gene does
provide greater certainty of the diagnosis, allows us to
better justify future screening for the development of new
lesions, and contributes to the genetic counseling and
preventive care of at-risk family members.
Fig. 1 a Color photograph
of the right eye illustrating a
retinal cavernous hemangioma.
b Fluorescein angiography of




Fig. 2 A family tree illustrating which family members were affected
by either a cerebral cavernous hemangioma, a retinal cavernous
hemangioma, or both tumors. (The arrow designates the patient in our
report)
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